A Promise Beyond Cancer
Envisioning the future of targeted therapeutics
Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Our focus is a multiple-targeted universal CAR T system with the potential to improve the lives of millions of patients across the world who are suffering from a wide range of malignancies.
Inspired and ambitious, our researchers have pioneered the BRiDGECAR™ system, which combines our nfP2X7-targeted universal CAR T with multiple targeted antibodies, and will potentially be capable of treating most forms of cancer.
We have several programs under development, targeting a number of liquid and solid tumours and, if successful, are one step closer to our vision of best-in-class treatment for a great number of cancer patients.